Global Information
회사소개 | 문의 | 비교리스트

라틴아메리카의 성욕감퇴장애(HSDD) 치료제 : 치료제 종류(부스피론, 부프로피온), 판매 경로(병원, 진료소, 온라인 소매업체), 국가별 - 세계 기회 분석 및 업계 예측(2020-2027년)

LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market by Treatment Type (Buspirone and Bupropion), Sales Channel (Hospitals, Clinics, and Online Retailers): Regional Opportunity Analysis and Industry Forecast, 2020-2027

리서치사 Allied Market Research
발행일 2020년 12월 상품 코드 991223
페이지 정보 영문 145 Pages
가격
US $ 3,039 ₩ 3,694,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 4,649 ₩ 5,651,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 5,105 ₩ 6,205,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,119 ₩ 8,653,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



라틴아메리카의 성욕감퇴장애(HSDD) 치료제 : 치료제 종류(부스피론, 부프로피온), 판매 경로(병원, 진료소, 온라인 소매업체), 국가별 - 세계 기회 분석 및 업계 예측(2020-2027년) LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market by Treatment Type (Buspirone and Bupropion), Sales Channel (Hospitals, Clinics, and Online Retailers): Regional Opportunity Analysis and Industry Forecast, 2020-2027
발행일 : 2020년 12월 페이지 정보 : 영문 145 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

라틴아메리카의 성욕감퇴장애(HSDD) 치료제 시장은 예측기간 중 3.8%의 연평균 복합 성장률(CAGR)로 확대되어 2019년 1억 3,100만 달러에서 2027년에는 1억 7,000만 달러 규모로 성장할 것으로 예측됩니다. 스트레스, 우울증, 불안, 장기 권태감 등의 생활습관병 증가, 의약품 사용 증가, 성기능 장애로 연결되는 수술 건수 증가 등의 요인이 시장 성장을 가속하고 있습니다. 한편, HSDD에 대한 낮은 인지도가 예측기간 중 시장 성장을 저해할 것으로 예측됩니다.

라틴아메리카의 성욕감퇴장애(HSDD: Hypoactive Sexual Desire Disorder) 치료제 시장을 조사했으며, 시장의 정의와 개요, 코로나19(COVID-19) 및 기타 시장 영향요인 분석, 시장 규모 추이와 예측, 추진 구분·용도·속도·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

제1장 서론

제2장 개요

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
  • Porter의 산업 분석
  • 주요 기업의 포지셔닝
  • 연간 지출
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
  • 영향 분석
  • COVID-19의 영향
  • 인지 행동 요법

제4장 시장 분석과 예측 : 약제 유형별

  • 부스피론(Buspirone)
  • 부프로피온(Buspirone)
    • 주요 동향, 성장요인, 성장 기회
    • 시장 분석 : 국가별

제5장 시장 분석과 예측 : 판매 경로별

  • 병원
  • 클리닉
  • 온라인 소매업체
    • 시장 분석 : 국가별

제6장 시장 분석과 예측 : 국가별

  • 브라질
  • 아르헨티나
  • 칠레
  • 콜롬비아
  • 에콰도르
  • 페루
  • 기타
    • 주요 동향과 성장 기회
    • 약제 유형별
    • 판매 경로별

제7장 기업 개요

  • AUROBINDO PHARMA
  • BRISTOL-MYERS SQUIBB COMPANY
  • GLAXOSMITHKLINE PLC(GSK)
  • MYLAN N.V.
  • NOVARTIS INTERNATIONAL AG
  • PALATIN TECHNOLOGIES, INC.
  • SPROUT PHARMACEUTICALS, INC.
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.(ACTAVIS GENERICS)
  • ZYDUS CADILA
LSH 21.03.10

LIST OF TABLES

  • TABLE 01.ANNUAL SPENDING ON WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT, BY COUNTRY, 2019 (US$)
  • TABLE 02.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 03.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019-2027 (NUMBER OF SESSIONS)
  • TABLE 04.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 ($MILLION)
  • TABLE 05.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE, 2019-2027 (MILLION UNITS)
  • TABLE 06.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 07.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 08.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 09.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 10.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 11.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 (MILLION UNITS)
  • TABLE 12.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 13.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 14.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 15.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 16.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 17.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 18.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 19.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019-2027 (MILLION UNITS)
  • TABLE 20.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 ($MILLION)
  • TABLE 21.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 (MILLION UNITS)
  • TABLE 22.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 23.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 (MILLION UNITS)
  • TABLE 24.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 ($MILLION)
  • TABLE 25.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 (MILLION UNITS)
  • TABLE 26.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 27.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 (MILLION UNITS)
  • TABLE 28.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 ($MILLION)
  • TABLE 29.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 (MILLION UNITS)
  • TABLE 30.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 31.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 (MILLION UNITS)
  • TABLE 32.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 ($MILLION)
  • TABLE 33.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 (MILLION UNITS)
  • TABLE 34.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 35.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 (MILLION UNITS)
  • TABLE 36.ECUADOR HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 ($MILLION)
  • TABLE 37.ECUADOR HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 (MILLION UNITS)
  • TABLE 38.ECUADOR HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 39.ECUADOR HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 (MILLION UNITS)
  • TABLE 40.PERU HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 ($MILLION)
  • TABLE 41.PERU HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 (MILLION UNITS)
  • TABLE 42.ECUADOR HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 43.PERU HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 (MILLION UNITS)
  • TABLE 44.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 ($MILLION)
  • TABLE 45.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019-2027 (MILLION UNITS)
  • TABLE 46.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 47.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019-2027 (MILLION UNITS)
  • TABLE 48.AUROBINDO: COMPANY SNAPSHOT
  • TABLE 49.AUROBINDO: PRODUCT PORTFOLIO
  • TABLE 50.BMS: COMPANY SNAPSHOT
  • TABLE 51.BMS: PRODUCT PORTFOLIO
  • TABLE 52.GSK: COMPANY SNAPSHOT
  • TABLE 53.GSK: OPERATING SEGMENTS
  • TABLE 54.GSK: PRODUCT PORTFOLIO
  • TABLE 55.MYLAN: COMPANY SNAPSHOT
  • TABLE 56.MYLAN: OPERATING BUSINESS SEGMENTS
  • TABLE 57.MYLAN: PRODUCT PORTFOLIO
  • TABLE 58.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 59.NOVARTIS: OPERATING SEGMENTS
  • TABLE 60.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 61.PALATIN: COMPANY SNAPSHOT
  • TABLE 62.PALATIN: PRODUCT PORTFOLIO
  • TABLE 63.SPROUT: COMPANY SNAPSHOT
  • TABLE 64.SPROUT: OPERATING SEGMENTS
  • TABLE 65.SPROUT: PRODUCT PORTFOLIO
  • TABLE 66.SPROUT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 67.SUN PHARMA: COMPANY SNAPSHOT
  • TABLE 68.SUN PHARMA: OPERATING SEGMENTS
  • TABLE 69.SUN PHARMA: PRODUCT PORTFOLIO
  • TABLE 70.TEVA: COMPANY SNAPSHOT
  • TABLE 71.TEVA: OPERATING SEGMENTS
  • TABLE 72.TEVA: PRODUCT PORTFOLIO
  • TABLE 73.ZYDUS: COMPANY SNAPSHOT
  • TABLE 74.ZYDUS: OPERATING SEGMENTS
  • TABLE 75.ZYDUS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET SEGMENTATION:
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIER
  • FIGURE 04.LOW BARGAINING POWER OF BUYERS
  • FIGURE 05.LOW THREAT OF SUBSTITUTES
  • FIGURE 06.HIGH INTENSITY OF RIVALRY
  • FIGURE 07.MODERATE THREAT OF NEW ENTRANT
  • FIGURE 08.TOP PLAYER POSITIONING, 2019
  • FIGURE 09.IMPACT ANALYSIS, LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET
  • FIGURE 10.AUROBINDO: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 11.AUROBINDO: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 12.BMS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 13.BMS: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 14.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 15.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 16.GSK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 17.MYLAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 18.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 19.NOVARTIS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 20.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 21.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 22.PALATIN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 23.SUN PHARMA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 24.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 25.SUN PHARMA: REVENUE SHARE, BY GEOGRAPHY, 2020 (%)
  • FIGURE 26.TEVA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 27.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 28.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 29.ZYDUS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 30.ZYDUS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 31.ZYDUS: REVENUE SHARE, BY REGION, 2020 (%)

The LATAM women hypoactive sexual desire disorder treatment market accounted for $131 million in 2019, and is expected to reach $170 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.

Hypoactive sexual desire disorder (HSDD) is the most common type of sexual dysfunction that occurs in adult women globally, manifested by lack of sex interest for a period of six months or more, owing to personal distress or fluctuating sex hormones during menstrual cycle. Hypoactive sexual desire disorder is also known as female sexual interest/arousal disorder. HSDD is currently on the rise in adult women population, which causes low self-confidence and less connection with partners.

Hypoactive sexual desire disorder is classified into primary, secondary, acquired and generalized, or situational. Accurate diagnosis of symptoms of HSDD is very critical to finalize the treatment procedure, which is either psychotherapy or pharmacotherapy. Pharmacotherapy comprises buspirone and bupropion off label non hormonal treatment for HSDD in women suffering from low libido associated with anxiety and depression. Moreover, cognitive behavior therapy is suggested to patients showing a positive response to counseling sessions with a sex therapist.

In addition, Flibanserin is currently the only drug approved by the US FDA (Food & Drug Administration) for treating HSDD in premenopausal women, owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.

The LATAM women hypoactive sexual desire disorder (HSDD) treatment market is expected to register substantial growth in the future, owing to rise in prevalence of lifestyle ailments, such as stress, depression, anxiety, and prolonged fatigue and rise in use of medicines, which induces the state of hypoactive sexual desire disorder. For instance, stress can lead to release of hormones such as cortisol and epinephrine. These hormones in high levels can lead to diminished sex drive. Similarly, depression is marked by depressed mood, decreased energy, and loss of interest in pleasurable activities. In addition, rise in number of surgical procedures, which leads to sexual dysfunction, are expected to boost the growth of LATAM women hypoactive sexual desire disorder treatment market during the forecast period. However, lack in awareness related to hypoactive sexual desire disorder are anticipated to hamper the market growth during the forecast period. For instance, For instance, there is a lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana. This contributes to low diagnosis of HSDD in these countries. Presence of strong pipeline products which present in late phases of clinical trials are expected to get approved for commercialization in the coming years. Hence, the presence of pipeline drugs offers a lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market.

The LATAM women hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, sales channel, and country. By treatment type, the market is categorized into buspirone and bupropion. On the basis of sales channel, it is divided into hospitals, clinics, and online retailers. Country wise, the LATAM women hypoactive sexual desire disorder treatment market size is studied across Brazil, Argentina, Chile, Colombia, Ecuador, Peru, and rest of the LATAM.

The key players operating in the LATAM women hypoactive sexual desire disorder treatment market include Aurobindo Pharma, Bristol-Myers Squibb Company, Glaxo Smith Kline (GSK), Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceuticals, Novartis (Sandoz), Sun Pharmaceutical Industries Ltd., and Cadila Healthcare (Zydus). Product launch and acquisition were the most common strategies adopted by the key players, which has led to expansion of their product offerings.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current global LATAM women hypoactive sexual desire disorder treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Treatment Type

Buspirone

Bupropion

By Sales Channel

Hospitals

Clinics

Online Retailers

By Country

Brazil

Argentina

Chile

Colombia

Ecuador

Peru

Rest of LATAM

List of key players profiled in the report:

  • Aurobindo Pharma
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • Mylan N.V.
  • Novartis AG
  • Palatin Technologies, Inc.
  • Sprout Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • Shanghai Fosun Pharmaceutical Co., Ltd.
  • Amneal Pharmaceuticals
  • Allergan plc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key Findings
    • 3.2.1.Top Winning Strategies
    • 3.2.2.Top investment pockets
  • 3.3.Key forces shaping LATAM women hypoactive sexual desire disorder treatment industry/market
  • 3.4.Top player positioning, 2019
  • 3.5.Annual Spending, 2019
  • 3.6.Market dynamics
    • 3.6.1.Drivers
      • 3.6.1.1.Surge in prevalence of lifestyle ailments
      • 3.6.1.2.Rise in use of medicines that induce hypoactive sexual desire disorder
      • 3.6.1.3.Rise in number of surgical procedures leading to sexual dysfunction
    • 3.6.2.Restraint
      • 3.6.2.1.Lack in awareness related to hypoactive sexual desire disorder
    • 3.6.3.Opportunity
      • 3.6.3.1.Presence of strong pipeline products
  • 3.7.Impact Analysis
  • 3.8.COVID-19 Impact Analysis on LATAM women hypoactive sexual desire disorder treatment market
  • 3.9.Cognitive Behavior Therapy
    • 3.9.1.Key market trends, growth factors, and opportunities
    • 3.9.2.Market analysis, by country

CHAPTER 4:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Buspirone
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market analysis, by country
  • 4.3.Bupropion
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market analysis, by country

CHAPTER 5:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Hospitals
    • 5.2.1.Market analysis, by country
  • 5.3.Clinics
    • 5.3.1.Market analysis, by country
  • 5.4.Online Retailers
    • 5.4.1.Market analysis, by country

CHAPTER 6:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY COUNTRY

  • 6.1.Overview
    • 6.1.1.Market size and forecast, by country
  • 6.2.Brazil
    • 6.2.1.Key market trends and growth opportunities
    • 6.2.2.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
    • 6.2.3.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
  • 6.3.Argentina
    • 6.3.1.Key market trends and growth opportunities
    • 6.3.2.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
    • 6.3.3.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
  • 6.4.Chile
    • 6.4.1.Key market trends and growth opportunities
    • 6.4.2.Chile hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
    • 6.4.3.Chile hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
  • 6.5.Colombia
    • 6.5.1.Key market trends and growth opportunities
    • 6.5.2.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
    • 6.5.3.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
  • 6.6.Ecuador
    • 6.6.1.Key market trends and growth opportunities
    • 6.6.2.Ecuador hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
    • 6.6.3.Ecuador hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
  • 6.7.Peru
    • 6.7.1.Key market trends and growth opportunities
    • 6.7.2.Peru hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
    • 6.7.3.Peru hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
  • 6.8.Rest of LATAM
    • 6.8.1.Key market trends and growth opportunities
    • 6.8.2.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
    • 6.8.3.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

CHAPTER 7:COMPANY PROFILES

  • 7.1.AUROBINDO PHARMA
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance.
  • 7.2.BRISTOL-MYERS SQUIBB COMPANY
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product Portfolio
    • 7.2.5.Business performance
  • 7.3.GLAXOSMITHKLINE PLC (GSK)
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance.
  • 7.4.MYLAN N.V.
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
  • 7.5.NOVARTIS INTERNATIONAL AG
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
  • 7.6.PALATIN TECHNOLOGIES, INC.
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance.
    • 7.6.6.Key strategic moves and developments
  • 7.7.SPROUT PHARMACEUTICALS, INC.
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Key strategic moves and developments
  • 7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
  • 7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
  • 7.10.ZYDUS CADILA
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance.
Back to Top
전화 문의
F A Q